304 related articles for article (PubMed ID: 3501954)
1. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
2. [Adoptive immunotherapy of malignant disease using LAK cells].
Kimoto Y; Taguchi T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):788-96. PubMed ID: 3260466
[TBL] [Abstract][Full Text] [Related]
3. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
4. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
6. [Adoptive immunotherapy of malignant diseases with LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):687-92. PubMed ID: 3493732
[TBL] [Abstract][Full Text] [Related]
7. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
8. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
9. [Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1884-9. PubMed ID: 3496050
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
[TBL] [Abstract][Full Text] [Related]
11. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
Robak T
Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
[No Abstract] [Full Text] [Related]
12. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Takai N; Tanaka R; Yoshida S; Hara N; Saito T
Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
[TBL] [Abstract][Full Text] [Related]
16. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
[TBL] [Abstract][Full Text] [Related]
17. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
18. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
19. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
20. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
